SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106, a Potential Best-in-Class ADC for Sarcoma
• First-in-human study of SOT106 to be initiated in second half of 2026, advancing a differentiated LRRC15 ADC toward early clinical signal;
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SOT106 for the treatment of osteosarcoma, reinforcing its potential as a targeted therapy for this high unmet need population.
SOTIO Presents Positive Results from Non-Human Primate Study of SOT106, a Potential Best-in-Class ADC for Treatment of Sarcoma
- Preclinical studies indicate that SOT106 (anti-LRRC15 ADC) is highly effective and well-tolerated with significant promise for treating sarcomas and potentially other LRRC15-positive malignancies;
- IND filing anticipated in Q4 2026;
- Program advancing towards clinical readiness and exploring partnering opportunities.
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced favorable preclinical results supporting the development of SOT106, its antibody-drug conjugate for the treatment of sarcoma, at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 12-15, 2025, in Boca Raton, FL.
SOTIO Announces Promotion of Vivi Boura to Chief Medical Officer
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the promotion of Vivi Boura, M.D., Ph.D., an accomplished oncologist with extensive experience leading the clinical development of novel cancer therapies, to chief medical officer.
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
